: This biotechnology firm was a standout, posting a 426% return in 2017. Its growth was driven by positive clinical trial results for its cholesterol-reducing drug candidate.

: Nine of the top ten performing stocks of the year were in the biotech sector. Companies like Vertex Pharmaceuticals (VRTX) (up 97%) and Dynavax Technologies (DVAX) (up 373%) succeeded based on FDA approvals and breakthrough trial data. high risk stocks to buy 2017

: The maker of Invisalign benefited from a near-monopoly on invisible braces, seeing a 131% increase as it expanded its training to thousands of dentists globally. : This biotechnology firm was a standout, posting